5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Ronnen, E. A.; Kondagunta, G. V.; Lau, C.; Fischer, P.; Ginsberg, M. S.; Baum, M.; Kim, S. T.; Chen, I.; Baum, C. M.; Motzer, R. J.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • B-RAF mutation is associated with altered patterns of negative feedback of MAPK signaling that correlate with increased output of the pathway and increased sensitivity to MEK inhibition
    Meeting Abstract

    Pratilas, C.; Grbovic, O.; Zhao, H.; Viale, A.; Solit, D.; Rosen, N.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102
    Meeting Abstract

    Philips, G.; Sanford, B.; Halabi, S.; Bajorin, D.; Small, E. J.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastorna multiforme (GBM)
    Meeting Abstract

    Nguyen, T. D.; Lassman, A. B.; Lis, E.; Rosen, N.; Shaffer, D. R.; Scher, H. I.; Deangelis, L. M.; Abrey, L. E.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM)
    Meeting Abstract

    Nguyen, T. D.; Lassman, A. B.; Lis, E.; Rosen, N.; Shaffer, D. R.; Scher, H. I.; Deangelis, L. M.; Abrey, L. E.
    Neuro-Oncology (2006)

    Fulltext@MSK | Save
  • Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-Α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Kim, S. T.; Baum, C. M.; Figlin, R. A.
    Annals of Oncology (2006)

    Fulltext@MSK | Save
  • Phase III randomized trial of sunitinib malate (SU1 1248) versus interferon-alfa (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Kim, S. T.; Baum, C. M.; Figlin, R. A.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Phase 2 trial of (177)Lutetium (Lu-177) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (Lu-177-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)
    Meeting Abstract

    Morris, M. J.; Milowsky, M. I.; Pandit-Taskar, N.; Divgi, C.; David, K. A.; Rozario, C. P.; Vallabhajosula, S.; Goldsmith, S. J.; Scher, H. I.; Nanus, D. M.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Phase 2 trial of trastuzumab (T) and KOS-953 (17-AAG) in patients (pts) with Her2-positive breast cancer: Preliminary results
    Meeting Abstract

    Modi, S.; Stopeck, A.; Linden, H. M.; Sugarman, S.; Ma, W.; Solit, D.; Rosen, N.; Kersey, K.; Johnson, R. G.; Hannah, A. L.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T)
    Meeting Abstract

    Modi, S.; Stopeck, A.; Gordon, M. S.; Solit, D.; Ma, W.; Wheler, J.; Cropp, G.; Johnson, R. G.; Hannah, A. L.; Hudis, C.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save